Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Impact of COVID-19 on treatment of MPNs

Naveen Pemmaraju • 15 May 2020
Myeloproliferative Neoplasms

Naveen Pemmaraju, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the impact of the current COVID-19 pandemic on the treatment of patients with myeloproliferative neoplasms (MPNs), highlighting the reduced access to routine healthcare in the outpatient setting. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Naveen Pemmaraju

1:40
TAG-AZA-VEN in the treatment of patients with newly diagnosed CD123+ AML
Naveen Pemmaraju • 11 Dec 2023
1:29
Exciting developments in the field of BPDCN
Naveen Pemmaraju • 11 Dec 2023
1:58
TRANSFORM-1: navitoclax + ruxolitinib vs placebo + ruxolitinib in patients with untreated MF
Naveen Pemmaraju • 11 Dec 2023
1:15
Exploring the evolving treatment landscape of myelofibrosis
Naveen Pemmaraju • 3 Jun 2023

Related Videos

2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
2:45
The addition of venetoclax to HMAs for the treatment of CMML: a retrospective PSM analysis
Douglas Tremblay • 9 Dec 2023
The content of VJHemOnc is intended for healthcare professionals